Cross-resistance to Lamivudine is irrelevant because Lamivudine will never be used by anyone as a second-line agent. Cross-resistance to Baraclude is relevant, of course.
Did you note the word short in the fifth paragraph of my previous post (#1391)?
The natap write-up you just cited come from trials where patients stayed on Tyzeka per the trial protocol even when it wasn’t effective. In the real world, however, such patients would be switched to another drug after a short course of treatment.
The real question is: Does Tyzeka produce cross-resistance to Baraclude in cases where Tyzeka doesn’t work more often than Baraclude produces cross-resistance to Tyzeka in cases where Baraclude doesn’t work? I don’t think we know the answer because the latter half of the question has not been sufficiently studied.
I’ve discussed this issue with NVS IR and they agreed with my analysis. Obviously, however, I’m not the one who needs to be convinced for the sales to start kicking in.
Market Data 
Markets 
AI
